FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.
Also in this 8-page Issue: Safety Warnings Are Added to Labels for Epo and Avastin.
Cancer Accounts for 23% of U.S. Deaths, American Cancer Society Says.
NCI Sets its Targets for Grant Success Rate and R01 Payline for FY05.
NIH Panel Calls for Further Research On End-of-Life Issues.
NAS Committee Urges Greater Rewards For Interdisciplinary Research.
CAM Therapies Should Be Held to Conventional Standards and Congress Should Toughen Dietary Supplements Act, IOM Panel Says.
Funding Opportunities Listed.
Trending Stories
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
- Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - Political appointees to be inserted into all stages of making research funding awards if OMB rule becomes final
